TNF and inflammatory bowel disease: The innate hyperactive chronic immune response in IBD is the primary exacerbator of tissue injury and the main cause of symptoms in patients, and recently, new therapies specifically designed to block the effects of TNF-α, such as infliximab, have shown promise by reducing tissue-associated inflammation in selected individuals [7].